Home | Publications | Therapeutic | Obesity place holder
place holder place holder

Obesity


Obesity Drug Discoveries: what the future holds + Obesity Tracker


Publication Date   August 2007
Publisher   Espicom
Product Type   Strategic Report
Pages   116
ISBN Number   978-1-85822-294-3
Product Code   ESP1023
Ask a question about this product?

Price £995.00

approximately: $1,971 | €1,265

Summary


Fully expanded and updated, Volume I: Europe contains over 570 detailed and fully verified profiles of specialist distributors in 42 countries from Armenia and Austria to Ukraine and the UK. Sales success in export markets requires local business and cultural knowledge - knowledge that can effectively be found via sales agents and distributors.

Whatever your sales representation needs this essential guide will help. Unlike simple listings, each profile has been researched and verified directly with the company by MediSTAT's researchers, and details provided include, where available:

  • Full address details with key named contact
  • Years established
  • Number of employees, including sales/servicing/administration split
  • Turnover
  • Product areas represented
  • Potential new product areas
  • Companies represented.

Please Note: The publisher will not fulfil orders to a personal email address, you must supply a work or business address.

Content


  • Executive summaryWhat is obesity?
  • Defining obesity
  • What causes obesity?
  • What effects does obesity have?
    • Figure 1: Effects of obesity on health
    • Table 1. Relative risks of health problems associated with obesity
      • The scale of the problem
      • Prevalence of obesity
    • Figure 2. Estimated global prevalence of obesity
      • Highest prevalence of obesity
        • Prevalence in the US
        • Prevalence in the UK
        • Prevalence in Europe
        • Prevalence in Asia
        • Prevalence in developing countries
    • Figure 3. Percentage of households having both underweight and overweight members in seven countries
    • Figure 4. Country comparison - percentage of adults with normal BMI
      • Childhood and future obesity
    • Figure 5. Percentage of population that is overweight
    • Figure 6. Predicted prevalence of obesity by 2025
      • The economic burden
      • US
      • UK
      • Europe
      • Developing Countries
      • The obesity therapy market
      • Competitor ratio analysis
      • Table 2. Competitor ratio analysis summary
      • Obesity management
      • Controlling energy balance
      • Achieving weight loss
      • Table 3. The benefits of a 10kg weight loss
      • Lifestyle modifications
      • Behaviour therapy
      • Pharmacotherapy
      • Surgery
      • Approved drugs for obesity management
    • Table 4. History of drug treatments for obesity
    • Table 5. Anti-obesity drugs approved for short-term use
    • Table 6. Anti-obesity drugs approved for long-term use
      • Acomplia
      • Approval History
      • Key Markets
      • Key Agreements
      • Clinical Trial Data
      • Safety Issues
      • Further Development
      • Sales
      • Sales Forecast
    • Figure 7. Acomplia reported and projected sales, 2006A-2012E (EUR million)
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • Meridia/Reductil
      • Approval History
      • Key Markets
      • Key Agreements
      • Clinical Trial Data
    • Table 7. Percentage change in subject's body weight at varying doses of sibutramine
    • Table 8. Health profile of subjects losing at least 5 per cent of body weight
      • Safety Issues
      • Further Development
      • Xenical/alli
      • Approval History
      • Key Markets
      • Key Agreements
      • Patent History
      • Clinical Trial Data
      • Safety Issues
      • Further Development
      • Sales
      • Sales Forecast
    • Figure 8. Reported and projected sales of Xenical 2001A-2011E
      • Regulatory authority guidelines for drug approval
      • Approval for additional indications
      • Potential new drugs
    • Table 9. Novel drugs in development by Phase
    • Table 10. Novel drugs in development by company
      • Drugs in clinical development
    • Figure 9. Estimated launch dates for profiled drugs
      • Beta3 adrenergic receptor modulators
      • Table 11. Beta3 adrenergic receptor modulators in development
      • KR P-204 (N-5984)
      • Safety Issues
      • Competitors
      • Launch Prediction
      • Cannabinoid receptor modulators
    • Table 12. Cannabinoid receptor modulators in development:
      • CP-945,598
      • Safety Issues
      • Competitors
      • Launch Prediction
      • taranabant
      • Safety Issues
      • Competitors
      • Launch Prediction
      • AVE 1625
      • Safety Issues
      • Competitors
      • Launch Prediction
      • SLV 319
      • Key Agreements
      • Safety Issues
      • Competitors
      • Launch Prediction
      • Digestive inhibitors/lipid metabolism modulators
    • Table 13. Digestive inhibitors/lipid metabolism modulators in development cetilistat
      • Key Agreements
      • Clinical Trial Data
      • Safety Issues
      • Further Developments
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • 869682
      • Safety Issues
      • Competitors
      • Launch Prediction
      • Histaminergic system modulators
    • Table 14. Histaminergic system modulators in development
      • OBE 101
    • Table 15. Properties of OBE101 and histamine compared
      • Key Agreements
      • Clinical Trial Data
      • Safety Issues
    • Table 16. Adverse effects of OBE101 when compared to anti-obesity medications currently in use
      • Patent History
      • Further Development
      • Competitors
      • Launch Prediction
      • Hormone analogues
    • Table 17. Hormone analogues in development pramlintide
      • Clinical Trial Data
      • Further Development
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • liraglutide
      • Clinical Trial Data
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • obinepitide
      • Patent History
      • Clinical Trial Data
      • Further Development
      • Safety Issues
      • Competitors
      • Launch Prediction
      • PYY 3-36
      • Key Agreements
      • Patent History
      • Clinical Trial Data
      • Further Development
      • Safety Issues
      • Competitors
      • Launch Prediction
      • Monoamine reuptake inhibitors/5-HT receptor modulators
    • Table 18. Monoamine reuptake inhibitors/5-HT receptor modulators in developmentlorcaserin
      • Patent History
      • Clinical Trial Data
    • Table 19. Incidence of FDA-defined valvulopathy
      • Further Development
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • tesofensine
      • Clinical Trial Data
      • Further Development
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Risks associated with drug development in therapeutic class
      • Neuropeptide receptor modulators
    • Table 20. Neuropeptide receptor modulators in development S-2367
      • Clinical Trial Data
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • Combination drugs
    • Table 21. Combination drugs in development
      • Contrave
      • Patent History
      • Clinical Trial Data
      • Further Developments
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • Qnexa
      • Clinical Trial Data
      • Further Development
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • pramlintide+phentermine/sibutramine
      • Safety Issues
      • Competitors
      • Launch Prediction
      • Empatic
      • Patent History
      • Clinical Trial Data
    • Table 22. Percentage change in body weight at week 24
      • Safety Issues
      • Launch Prediction
      • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
      • Recently-terminated p rogrammes
      • AMG 076
      • AOD 9604
      • Clinical Trial Data
      • CP-741952
      • CYT 009-GhrQb
      • Clinical Trial Data
      • oleoyl-estrone
      • Patent History
      • Clinical Trial Data
      • Further Development
      • PF-431499
      • The f uture of obesity treatment
      • Towards an all-encompassing cure; targeting the metabolic syndrome?
      • Recent advances and future developments
      • CD 36
      • Targeting ghrelin
      • Vaccines
      • Gene therapy
      • RNA interference
      • Conclusions
      • Sources
      • Espicom sources
      • Others